Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Is Covid Accelerating Cognitive Decline? Long-Covid Patients Face Alarming Risks

by Team Lumida
April 14, 2025
in Health and Longevity
Reading Time: 5 mins read
A A
0
Pandemic Aftershocks: Why Illnesses Are Surging Worldwide
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • Millions of long-Covid patients continue to experience cognitive difficulties, with some being diagnosed with mild cognitive impairment (MCI), a condition that can precede dementia or Alzheimer’s disease.
  • Studies suggest older adults with long Covid are at a higher risk of developing moderate to severe cognitive impairments, with up to one-third of long-Covid patients over 65 meeting MCI criteria.
  • Younger patients also report brain fog and memory issues, often linked to fatigue, pain, and other long-Covid symptoms, though their recovery may be more likely.
  • Neurologists warn that Covid-19 may accelerate cognitive decline in those already at risk, with brain inflammation and structural changes playing a key role.

What Happened?

Five years after the pandemic began, long-Covid patients are grappling with persistent cognitive issues, including memory loss, difficulty multitasking, and brain fog. These symptoms are severe enough to leave many unable to work, as seen in cases like Ken Todd, a 56-year-old former executive, and Juan Lewis, a 59-year-old retired Air Force officer.

Research shows that older adults with long Covid are particularly vulnerable. A study led by Dr. Gabriel de Erausquin found that long-Covid patients over 65 are four to five times more likely to meet the criteria for MCI compared to the general population. Younger patients, while less likely to develop MCI, still face significant cognitive challenges that may improve with rehabilitation.

Neurologists believe brain inflammation, genetic predispositions, and structural changes in the brain are contributing factors. Loss of smell, a common symptom of Covid-19, has also been linked to higher risks of cognitive decline.


Why It Matters?

The long-term cognitive effects of Covid-19 could have profound implications for public health, particularly as the population ages. MCI is often a precursor to dementia, and the rising prevalence among long-Covid patients raises concerns about a potential surge in Alzheimer’s cases in the coming years.

For younger patients, cognitive difficulties can disrupt careers and daily life, highlighting the need for effective rehabilitation and long-term monitoring. The uneven recovery trajectory, with some patients improving and others worsening, underscores the complexity of long Covid’s neurological impact.

The findings also emphasize the importance of early intervention and research into treatments that could mitigate cognitive decline in long-Covid patients.


What’s Next?

Ongoing studies, such as Dr. de Erausquin’s global research on 4,000 older adults with long Covid, aim to better understand the link between Covid-19 and cognitive decline. Meanwhile, rehabilitation programs are being developed to help patients manage symptoms and improve quality of life.

Healthcare providers will need to prepare for the long-term burden of cognitive impairments in long-Covid patients, including increased demand for neurological care and support services. Public health initiatives may also focus on identifying at-risk individuals and providing early interventions to prevent further decline.

As research progresses, the medical community will continue to explore whether long-Covid-related cognitive impairments are reversible or if they signal a broader shift in how aging and brain health are understood.

Source
Previous Post

AI Weather Models Revolutionize Forecasting With Hyper-Local Predictions

Next Post

TotalEnergies Projects First-Quarter Production Growth and Refining Margin Uptick

Recommended For You

America’s Protein Obsession Fuels a Booming Market, But Experts Are Concerned

by Team Lumida
1 month ago
black magnifying glass on white and brown marble table

Key Takeaways: Powered by lumidawealth.com Americans are consuming protein in unprecedented ways, with food companies introducing protein-infused products like chips, candy, coffee, and even water. The trend is driven...

Read more

Emerging Drugs from Lilly, Amgen, and Novartis Target Untreatable Cholesterol Linked to Heart Disease

by Team Lumida
2 months ago
white and blue medication pill blister pack

Key Takeaways: Powered by lumidawealth.com Lipoprotein(a), a genetic cholesterol variant untreatable by statins, increases the risk of heart attacks and strokes by 2-3 times for 1-2 billion people worldwide....

Read more

Doctors and Patients Struggle With Trust Amid a Broken Healthcare System

by Team Lumida
2 months ago
person sitting while using laptop computer and green stethoscope near

Key Takeaways: Powered by lumidawealth.com Trust between doctors and patients is eroding, with both sides frustrated by systemic issues like rushed appointments, corporate quotas, and communication breakdowns. Doctors cite...

Read more

U.S. Drug Overdose Deaths Decline by 25%, Marking Progress in the Fentanyl Crisis

by Team Lumida
2 months ago
round white pills

Key Takeaways: Powered by lumidawealth.com Overdose deaths in the U.S. dropped by 25% in the 12 months ending October 2024, with 82,000 fatalities reported. The decline is largely driven...

Read more

Retirement Health Worries: Navigating Dementia and Heart Risks in the Golden Years

by Team Lumida
3 months ago
woman in purple polo shirt wearing eyeglasses

Key Takeaways: Powered by lumidawealth.com Retirement often brings increased focus on health concerns, including cognitive decline and heart disease. Family history plays a significant role in health risks, prompting...

Read more

CVS Bets on Pharmacy-First Strategy with Smaller, Streamlined Stores

by Team Lumida
3 months ago
CVS Bets on Pharmacy-First Strategy with Smaller, Streamlined Stores

Key Takeaways: Powered by lumidawealth.com CVS is launching 12 smaller stores focused on pharmacy services, cutting back on traditional retail offerings. The move reflects a response to declining retail...

Read more

TreeHouse Foods Faces Slowdown as Shoppers Cut Back on Even Cheaper Groceries

by Team Lumida
3 months ago
high-angle photography of grocery display gondola

Key Takeaways Powered by lumidawealth.com TreeHouse Foods, a major supplier of private-label goods for retailers like Walmart and Target, is experiencing slower sales growth as inflation-weary consumers reduce spending...

Read more

Mixue Overtakes McDonald’s as the World’s Largest Food Chain by Locations

by Team Lumida
3 months ago
a mcdonald's sign with a cloudy sky in the background

Key Takeaways: Powered by lumidawealth.com Mixue Ice Cream and Tea now operates 45,000 stores globally, surpassing McDonald’s and Starbucks in total locations. The Chinese chain’s low-cost model, with products...

Read more

401(k) Millionaires Surge 27% in 2024 Amid Market Gains and Higher Savings

by Team Lumida
3 months ago
401(k) Millionaires Surge 27% in 2024 Amid Market Gains and Higher Savings

Key Takeaways: Powered by lumidawealth.com The number of 401(k) millionaires rose 27% in 2024, reaching 537,000, driven by strong market performance and increased contribution rates. Average 401(k) and IRA...

Read more

AstraZeneca’s Breast Cancer Drug Camizestrant Shows Promising Late-Stage Trial Results

by Team Lumida
3 months ago
person holding white and orange plastic bottle

Key Takeaways: Powered by lumidawealth.com AstraZeneca’s experimental breast cancer drug, Camizestrant, demonstrated significant improvement in progression-free survival compared to standard treatments in a late-stage trial. The drug, combined with...

Read more
Next Post
TotalEnergies Projects First-Quarter Production Growth and Refining Margin Uptick

TotalEnergies Projects First-Quarter Production Growth and Refining Margin Uptick

blue and red cargo ship

China’s Port Activity Slows as U.S. Tariffs Hit Exports

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Crypto Market Awaits Election Impact

Crypto Market Awaits Election Impact

October 14, 2024
two women standing next to each other in front of a laptop

U.S. Jobs Surge Past Expectations: December Adds 256,000 Positions, Challenging Fed Rate Cut Timeline

January 11, 2025

Fed Rate Cuts Propel Bitcoin Over $62K: Expert Predictions Inside

September 19, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018